Consensus Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-02-11 pm EST			5-day change	1st Jan Change
55.94 ^USD	+0.74%		-5.38%	-1.10%

Feb. 10	Daiwa Securities Adjusts Bristol-Myers Squibb Price Target to $60 From $65, Maintains Outperform Rating	MT
Feb. 10	Bristol Myers Squibb Sees Positive Results for Breyanzi in Lymphoma Trials	DJ

Evolution of the Average Target: Bristol-Myers Squibb Company

Evolution of the Target Price: Bristol-Myers Squibb Company

Changes in Analyst Recommendations: Bristol-Myers Squibb Company

86a93c3f8517.q_UkvcH3pTsaT_SewRdJOebfpI5wLkW7Cw1nv659kks.5ZRBjrmc0EN_KLPTqVN8QJ6ckPs5XD2KZEAS9Zsfwxj6rQmMp5jCCE4BxA~10d35372b9424f1f5deb6c09db618c10

Analysts' recommendations: Bristol-Myers Squibb Company

Daiwa Securities Adjusts Bristol-Myers Squibb Price Target to $60 From $65, Maintains Outperform Rating	Feb. 10	MT
Deutsche Bank Adjusts Bristol-Myers Squibb Price Target to $53 From $55, Maintains Hold Rating	Feb. 10	MT
Leerink Partners Adjusts Price Target on Bristol-Myers Squibb to $68 From $73	Feb. 07	MT
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $62 From $60	Feb. 07	MT
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb to $37 From $39	Feb. 07	MT
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $67 From $65	Feb. 07	MT
Cantor Fitzgerald Adjusts Bristol-Myers Squibb Price Target to $55 From $50, Maintains Neutral Rating	Feb. 04	MT
Citigroup Adjusts Price Target on Bristol-Myers Squibb to $65 From $60, Keeps Neutral Rating	Jan. 28	MT
TD Cowen Adjusts Price Target on Bristol-Myers Squibb to $64 From $59	Jan. 27	MT
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $52 From $53, Maintains Neutral Rating	Jan. 10	MT
Truist Raises Price Target on Bristol-Myers Squibb to $65 From $62, Keeps Buy Rating	Jan. 08	MT
Jefferies Upgrades Bristol-Myers Squibb to Buy From Hold, Adjusts Price Target to $70 From $63	Dec. 16	MT
Berenberg Raises Price Target on Bristol-Myers Squibb to $60 From $55, Keeps Hold Rating	Dec. 10	MT
Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating	Nov. 25	MT
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $60 From $52, Maintains Equalweight	Nov. 18	MT
HSBC Adjusts Bristol-Myers Squibb Price Target to $58 From $50, Maintains Hold Rating	Nov. 15	MT
JPMorgan Adjusts Price Target on Bristol-Myers Squibb to $70 From $64, Keeps Overweight Rating	Nov. 13	MT
Analyst recommendations: Spotify, Starbucks, Tesla, Block, Coinbase...	Nov. 13
Daiwa Upgrades Bristol-Myers Squibb to Outperform From Neutral, Adjusts Price Target to $65 From $50	Nov. 13	MT
UBS Raises Bristol-Myers Squibb Price Target to $60 From $54, Maintains Neutral Rating	Nov. 12	MT
Goldman Sachs Adjusts Bristol-Myers Squibb Price Target to $65 From $62, Maintains Buy Rating	Nov. 12	MT
Leerink Partners Upgrades Bristol-Myers Squibb to Outperform From Market Perform, Adjusts Price Target to $73 From $55	Nov. 12	MT
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb to $39 From $36, Keeps Underweight Rating	Nov. 12	MT
BMO Capital Adjusts Price Target on Bristol-Myers Squibb to $61 From $57, Keeps Market Perform Rating	Nov. 12	MT
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $53 From $50, Keeps Neutral Rating	Nov. 12	MT

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	BRISTOL-MYERS SQUIBB COMPANY					+9.48%
	ELI LILLY AND COMPANY					+13.28%
	JOHNSON & JOHNSON					+8.01%
	NOVO NORDISK A/S					+37.7%
	ABBVIE INC.					+6.81%
	ROCHE HOLDING AG					+6.64%
	ASTRAZENECA PLC					+20.92%
	MERCK & CO., INC.					+34.82%
	NOVARTIS AG					+6.71%
	AMGEN INC.					+6.75%
	Average					+15.11%
	Weighted average by Cap.					+15.49%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

55.94USD

Average target price

61.24USD

Spread / Average Target

+9.48%

High Price Target

70.00USD

Spread / Highest target

+25.13%

Low Price Target

37.00USD

Spread / Lowest Target

-33.86%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Daiwa Securities
Deutsche Bank Securities
Leerink Partners
Wells Fargo Securities
Morgan Stanley
Goldman Sachs
Cantor Fitzgerald
Citigroup
TD Cowen
Redburn Atlantic
Truist Securities
Jefferies & Co.
Berenberg Bank
Bernstein
HSBC
JPMorgan Chase
UBS
BMO Capital
Barclays
Wolfe Research
Societe Generale
Redburn
BofA Securities
William Blair & Co.
Credit Suisse
Atlantic Equities
Guggenheim
Raymond James
Argus